Case Study: a USA-based biopharmaceutical company maintains IND status with Freyr

a USA-Based Biopharmaceutical Company maintains IND 064179 status with FREYR

A USA-based biopharmaceutical company needed to respond to a USFDA pre-termination letter to maintain the active status of its IND 064179. Facing challenges due to a lack of prior regulatory submission experience, the company engaged FREYR for end-to-end regulatory support and compliance services.

FREYR provided a comprehensive solution, evaluating the FDA letter and preparing a strategic, compliant response submitted on time. This successful intervention by FREYR minimized the risk of termination and resulted in the IND maintaining its active status.